German study reveals Real-World use of PRRT for neuroendocrine tumors
NCT ID NCT07653126
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 117 people with gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) who received a type of radiation therapy called PRRT in German clinics. Researchers collected information on patient characteristics, treatment timing, and how PRRT was given in everyday practice. The goal was to better understand real-world treatment patterns, not to test a new drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE/DOTATOC or Lutathera®
What this could lead to
If successful, this study could help doctors better understand how PRRT is used in real-world settings, potentially improving treatment guidelines for neuroendocrine tumors.
What could go wrong
This is a retrospective observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other countries or healthcare systems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRO-ENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Essen, Germany
-
Novartis Investigative Site
Heidelberg, Germany
-
Novartis Investigative Site
München, Germany
-
Novartis Investigative Site
Rostock, Germany
-
Novartis Investigative Site
Stuttgart, Germany
-
Novartis Investigative Site
Tübingen, Germany
-
Novartis Investigative Site
Würzburg, Germany